Citigroup
VIRX

Citigroup’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Citigroup’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-28
Closed -$4K – 7366
2016
Q4 		$4K Sell
28
-9
-24% -$1.25K ﹤0.01% 6986
2016
Q3 		$6K Sell
37
-12
-24% -$1.69K ﹤0.01% 6736
2016
Q2 		$6K Buy
49
+14
+40% +$1.55K ﹤0.01% 6734
2016
Q1 		$4K Buy
35
+7
+25% +$1.06K ﹤0.01% 7091
2015
Q4 		$5K Buy
28
+17
+155% +$3.18K ﹤0.01% 7067
2015
Q3 		$2K Buy
11
+10
+1,000% +$3.61K ﹤0.01% 7063
2015
Q2 		$1K Buy
+1
New +$531 ﹤0.01% 7354

Other funds holding VIRX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Citigroup's VIRX Position: Q1 2023 in Review

Citigroup sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q1 2023, closing a stake of 98 shares — an estimated $143 sold.

Citigroup first reported a position in VIRX in Q3 2013 and held it in 18 quarters. The position peaked at $311K in Q1 2021. 48 funds tracked by Wall St. Rank hold VIRX as of Q1 2023.

  • Citigroup reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Citigroup sold 98 Viracta Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $143.
  • Citigroup first reported a position in Viracta Therapeutics, Inc. Common Stock in Q3 2013 and held it in 18 quarters.
  • Citigroup's Viracta Therapeutics, Inc. Common Stock position peaked at $311K in Q1 2021.
  • 48 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Citigroup's 13F filing for Q1 2023, filed 11 May 2023.